|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
|
RS53594B1
(sr)
*
|
2004-07-22 |
2015-02-27 |
Genentech, Inc. |
Preparat her2 antitela
|
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
BRPI0518086A
(pt)
*
|
2004-12-07 |
2008-10-28 |
Genentech Inc |
métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
|
|
ATE414718T1
(de)
|
2005-01-05 |
2008-12-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
CN102580084B
(zh)
*
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
|
MX2007009889A
(es)
|
2005-02-23 |
2007-09-07 |
Genentech Inc |
Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
|
|
CA2601936C
(en)
*
|
2005-02-24 |
2014-06-17 |
Amgen Inc. |
Epidermal growth factor receptor mutations
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
PL1919503T3
(pl)
|
2005-08-10 |
2015-04-30 |
Macrogenics Inc |
Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
|
|
JP5537035B2
(ja)
*
|
2006-02-10 |
2014-07-02 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
|
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
|
ES2489646T3
(es)
*
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
WO2008073160A2
(en)
*
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US8652466B2
(en)
*
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
WO2009151717A2
(en)
|
2008-04-02 |
2009-12-17 |
Macrogenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
|
HUE066143T2
(hu)
|
2007-06-26 |
2024-07-28 |
F Star Therapeutics Ltd |
Kötõágensek megjelenítése
|
|
WO2009013305A1
(en)
*
|
2007-07-24 |
2009-01-29 |
Novartis Ag |
Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
|
|
RU2370280C2
(ru)
*
|
2007-10-08 |
2009-10-20 |
Институт физико-химической биологии им. А.Н.Белозерского |
СПОСОБ СУПЕРПРОДУКЦИИ В РАСТЕНИИ АНТИТЕЛ ПРОТИВ ОНКОГЕНА HER2/neu
|
|
TWI472339B
(zh)
*
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
PT2247304T
(pt)
*
|
2008-04-02 |
2016-08-29 |
Macrogenics Inc |
Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Ｈｅｒ２サブセット
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
EP2318832B1
(en)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
|
CN102753193A
(zh)
|
2008-10-31 |
2012-10-24 |
比奥根艾迪克Ma公司 |
Light靶向分子及其用途
|
|
EP2546347A3
(en)
*
|
2009-02-25 |
2013-05-01 |
Merck Sharp & Dohme Corp. |
Glycoprotein composition from engineered galactose assimilation pathway in Pichia pastoris
|
|
US20110313137A1
(en)
*
|
2009-02-25 |
2011-12-22 |
Dongxing Zha |
Her2 antibody compositions
|
|
US8064431B2
(en)
*
|
2009-07-14 |
2011-11-22 |
Level 3 Communications, Llc |
One way information transmission method
|
|
US8401035B2
(en)
*
|
2009-07-14 |
2013-03-19 |
Level 3 Communications, Llc |
One way SRS information transmission method
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10584181B2
(en)
|
2009-12-04 |
2020-03-10 |
Genentech, Inc. |
Methods of making and using multispecific antibody panels and antibody analog panels
|
|
WO2011084496A1
(en)
*
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
SG10201604336VA
(en)
|
2010-03-04 |
2016-07-28 |
Macrogenics Inc |
Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
|
|
RU2425840C1
(ru)
*
|
2010-04-09 |
2011-08-10 |
Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") |
АНТИТЕЛО, СПЕЦИФИЧЕСКИ ВЗАИМОДЕЙСТВУЮЩЕЕ С ОНКОБЕЛКОМ HER2/neu
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
WO2011130580A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US9217039B2
(en)
|
2010-11-01 |
2015-12-22 |
Symphogen A/S |
Anti-HER3 antibodies and compositions
|
|
CN103702967A
(zh)
|
2011-03-14 |
2014-04-02 |
貝丝以色列女执事医疗中心 |
用于治疗增殖性病症的方法和组合物
|
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
WO2013055874A2
(en)
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
NZ629283A
(en)
*
|
2012-03-16 |
2016-04-29 |
Covagen Ag |
Novel binding molecules with antitumoral activity
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
RU2014145830A
(ru)
|
2012-04-17 |
2016-06-10 |
Арсанис Байосайенсиз Гмбх |
Перекрестно-реактивные антитела против staphylococcus aureus
|
|
ES2431914B2
(es)
*
|
2012-04-27 |
2014-07-24 |
Universidad De Cádiz |
Anticuerpo monoclonal humano ANTI-HER2
|
|
EP2855531A1
(en)
*
|
2012-05-24 |
2015-04-08 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
EP2858648B1
(en)
|
2012-06-07 |
2018-08-22 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the inhibition of pin1
|
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
|
US20160038490A1
(en)
*
|
2012-07-18 |
2016-02-11 |
Angion Biomedica Corp. |
Compositions and methods for treating dysproliferative diseases
|
|
MX357675B
(es)
|
2012-08-13 |
2018-07-18 |
Genentech Inc |
Anticuerpos anti-jagged y métodos de uso.
|
|
EP2885311B1
(en)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
DK2839860T3
(da)
|
2012-10-12 |
2019-06-17 |
Medimmune Ltd |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
IL238323B2
(en)
|
2012-10-30 |
2023-11-01 |
Esperance Pharmaceuticals Inc |
Antibody/drug conjugates and methods of use
|
|
EP2738180A1
(en)
*
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
EP2931318A4
(en)
*
|
2012-12-13 |
2016-07-20 |
Univ Pennsylvania |
DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
US9458245B2
(en)
|
2013-03-06 |
2016-10-04 |
Merrimack Pharmaceuticals, Inc. |
ANTI-C-MET tandem Fc bispecific antibodies
|
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
|
MX2015014181A
(es)
|
2013-04-09 |
2016-05-24 |
Boston Biomedical Inc |
2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
|
|
AR095863A1
(es)
|
2013-04-16 |
2015-11-18 |
Genentech Inc |
Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
|
|
AU2014262566A1
(en)
|
2013-05-08 |
2015-11-12 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
WO2015035337A1
(en)
|
2013-09-06 |
2015-03-12 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
|
|
JP2016538283A
(ja)
|
2013-11-13 |
2016-12-08 |
ザイムワークス，インコーポレイテッド |
Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
|
|
RS62157B1
(sr)
|
2013-11-19 |
2021-08-31 |
Remegen Co Ltd |
Anti-her2 antitelo i njegov konjugat
|
|
ES3030987T3
(en)
|
2013-11-27 |
2025-07-03 |
Zymeworks Bc Inc |
Bispecific antigen-binding constructs targeting her2
|
|
CA2925677A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
IL320281A
(en)
|
2013-12-25 |
2025-06-01 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibodies and methods for producing same
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
PH12020552271A1
(en)
|
2014-01-31 |
2022-05-02 |
Daiichi Sankyo Co Ltd |
Anti-her2 antibody-drug conjugate
|
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
EP3502134B1
(en)
|
2014-03-11 |
2020-12-16 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
ES2800674T3
(es)
*
|
2014-03-21 |
2021-01-04 |
X Body Inc |
Polipéptidos biespecíficos de unión a antígeno
|
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
EP3130608B1
(en)
|
2014-04-10 |
2019-09-04 |
Daiichi Sankyo Co., Ltd. |
(anti-her2 antibody)-drug conjugate
|
|
JP6983511B2
(ja)
|
2014-04-25 |
2021-12-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脳中の転移乳癌および他の癌を処置するための方法および組成物
|
|
WO2015164665A1
(en)
|
2014-04-25 |
2015-10-29 |
Genentech, Inc. |
Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
|
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
|
CA2950440A1
(en)
*
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
AU2015267051B2
(en)
|
2014-05-27 |
2022-03-17 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
CN106714829A
(zh)
|
2014-05-28 |
2017-05-24 |
中央研究院 |
抗TNF‑α醣抗体及其用途
|
|
US9968579B2
(en)
|
2014-07-17 |
2018-05-15 |
Beth Isreal Deaconess Medical Center, Inc. |
ATRA for modulating Pin1 activity and stability
|
|
WO2016011265A2
(en)
|
2014-07-17 |
2016-01-21 |
Beth Israel Deaconess Medical Center, Inc. |
Biomarkers for pin1-associated disorders
|
|
KR101608301B1
(ko)
|
2014-08-22 |
2016-04-12 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
|
KR102508173B1
(ko)
*
|
2014-09-12 |
2023-03-10 |
제넨테크, 인크. |
항-her2 항체 및 면역콘주게이트
|
|
HK1243629A1
(zh)
|
2014-09-17 |
2018-07-20 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
|
|
CN104225594B
(zh)
*
|
2014-09-23 |
2016-03-23 |
合肥瀚科迈博生物技术有限公司 |
抗her2人源化抗体及其相关的抗肿瘤组合物
|
|
DK3223848T3
(da)
|
2014-11-27 |
2025-03-03 |
Zymeworks Bc Inc |
Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2
|
|
CA2969214A1
(en)
|
2014-12-01 |
2016-06-09 |
The Trustees Of The University Of Pennsylvania |
Dna antibody constructs and method of using same
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
|
CN105985435B
(zh)
*
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
US10548864B2
(en)
|
2015-03-12 |
2020-02-04 |
Beth Israel Deaconess Medical Center, Inc. |
Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
|
|
WO2016168769A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
|
CA2984458A1
(en)
|
2015-05-13 |
2016-11-17 |
Zymeworks Inc. |
Antigen-binding constructs targeting her2
|
|
CN107614015A
(zh)
|
2015-05-30 |
2018-01-19 |
豪夫迈·罗氏有限公司 |
治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
|
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
|
US20180140572A1
(en)
|
2015-06-03 |
2018-05-24 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
US11173213B2
(en)
|
2015-06-29 |
2021-11-16 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
CN105132357B
(zh)
*
|
2015-07-29 |
2019-12-06 |
苏州诺普再生医学有限公司 |
一种用于表皮细胞培养的无血清培养体系
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3353288A1
(en)
|
2015-09-22 |
2018-08-01 |
H. Hoffnabb-La Roche Ag |
Expression of fc-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
CN108779174B
(zh)
*
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI778491B
(zh)
|
2015-11-30 |
2022-09-21 |
美商輝瑞股份有限公司 |
位點專一性ｈｅｒ２抗體藥物共軛體
|
|
KR20180114210A
(ko)
|
2016-03-08 |
2018-10-17 |
아카데미아 시니카 |
N-글리칸의 모듈 합성 방법 및 그의 어레이
|
|
RU2648161C2
(ru)
*
|
2016-04-01 |
2018-03-22 |
Юрий Леонидович Дорохов |
Способ получения антитела, специфически связывающего домен димеризации экзоклеточной части онкобелка HER2/neu, в растении, антитело, полученное этим способом, и его применение
|
|
US10961311B2
(en)
|
2016-04-15 |
2021-03-30 |
Macrogenics, Inc. |
B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
KR101923624B1
(ko)
|
2016-07-28 |
2018-11-30 |
고려대학교 산학협력단 |
암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
|
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
|
CN109862919A
(zh)
|
2016-10-11 |
2019-06-07 |
免疫医疗有限公司 |
抗体-药物缀合物联合免疫介导的治疗剂
|
|
AU2017355432A1
(en)
|
2016-11-04 |
2019-05-16 |
F. Hoffmann-La Roche Ag |
Treatment of HER2-positive breast cancer
|
|
KR101923641B1
(ko)
|
2016-11-25 |
2018-11-29 |
재단법인 목암생명과학연구소 |
항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
|
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
CN110049779A
(zh)
|
2016-12-12 |
2019-07-23 |
第一三共株式会社 |
抗体-药物缀合物和免疫检查点抑制剂的组合
|
|
CN110099926A
(zh)
|
2016-12-28 |
2019-08-06 |
豪夫迈·罗氏有限公司 |
晚期her2表达性癌症的治疗
|
|
WO2018124766A2
(ko)
|
2016-12-28 |
2018-07-05 |
주식회사 녹십자랩셀 |
키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
|
|
KR20210134432A
(ko)
*
|
2017-01-17 |
2021-11-09 |
제넨테크, 인크. |
피하 her 2 항체 제형
|
|
EP3572428A4
(en)
|
2017-01-17 |
2020-12-30 |
Daiichi Sankyo Company, Limited |
ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
|
|
JP7252526B2
(ja)
|
2017-01-23 |
2023-04-05 |
スチョー アルファマブ カンパニー リミテッド |
Ｐｄ－ｌ１結合ポリペプチド又は化合物
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
EP3579848B1
(en)
|
2017-02-08 |
2024-10-30 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
JP7685821B2
(ja)
*
|
2017-02-20 |
2025-05-30 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
|
|
LT3589661T
(lt)
|
2017-03-02 |
2024-02-12 |
Genentech, Inc. |
Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas
|
|
US11207420B2
(en)
|
2017-04-19 |
2021-12-28 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Cytotoxin and conjugate, uses of same and preparation method therefor
|
|
JP2020517273A
(ja)
|
2017-04-24 |
2020-06-18 |
ジェネンテック， インコーポレイテッド |
膜貫通ドメインまたは膜近傍ドメインにおけるＥｒｂＢ２／Ｈｅｒ２突然変異
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TW202530271A
(zh)
|
2017-05-15 |
2025-08-01 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
CA3062656A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
KR20250084239A
(ko)
|
2017-08-31 |
2025-06-10 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 개량 제조 방법
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
JP7710706B2
(ja)
|
2017-09-25 |
2025-07-22 |
シーフイダ ファーマシューティカル グループ （チーリン） カンパニー リミテッド |
癌治療のための方法及び組成物
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
JP7386796B2
(ja)
|
2017-11-14 |
2023-11-27 |
グリーン クロス ラボ セル コーポレーション |
抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
|
|
CA3080236A1
(en)
|
2017-12-15 |
2019-06-20 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Bioactive molecule conjugate, preparation method and use thereof
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
MX2020008336A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
EP3773676A4
(en)
*
|
2018-04-03 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
BR112020016997A2
(pt)
|
2018-04-13 |
2021-01-19 |
F. Hoffmann-La Roche Ag |
Moléculas de ligação e de ácido nucleico isolada, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
US12479926B2
(en)
|
2018-05-18 |
2025-11-25 |
Daiichi Sankyo Co., Ltd. |
Anti-MUC1 antibody-drug conjugate
|
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
US12220604B2
(en)
|
2018-07-31 |
2025-02-11 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
|
|
EP3830124A1
(en)
|
2018-08-01 |
2021-06-09 |
Cephalon, Inc. |
Anti-cxcr2 antibodies and uses thereof
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
SG11202101298XA
(en)
|
2018-08-08 |
2021-03-30 |
Dragonfly Therapeutics Inc |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
US12336995B2
(en)
|
2018-09-10 |
2025-06-24 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
TWI848832B
(zh)
|
2018-10-15 |
2024-07-11 |
美商建南德克公司 |
用曲妥珠單抗安坦辛治療殘存乳癌之方法
|
|
WO2020084503A1
(en)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
A composition comprising antibody with reduced level of basic variants thereof
|
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
|
US20220387618A1
(en)
|
2019-11-15 |
2022-12-08 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
|
|
CA3081503A1
(en)
|
2019-12-06 |
2021-06-06 |
Zymeworks Inc. |
Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
AR122018A1
(es)
|
2020-05-06 |
2022-08-03 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a nkg2d, cd16 y clec12a
|
|
PE20231361A1
(es)
|
2020-06-23 |
2023-09-05 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2
|
|
EP4171748A1
(en)
|
2020-06-29 |
2023-05-03 |
Genentech, Inc. |
Pertuzumab plus trastuzumab fixed dose combination
|
|
BR112023000707A2
(pt)
|
2020-07-14 |
2023-01-31 |
Hoffmann La Roche |
Ensaio de ligação para uma combinação de dose fixa, proteína, kits, composições e métodos para avaliar uma composição de dose fixa, fazer uma composição e para analisar o teor de proteína de uma combinação de dose fixa
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
CN119504997A
(zh)
|
2021-02-09 |
2025-02-25 |
苏州宜联生物医药有限公司 |
生物活性物偶联物及其制备方法和用途
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
CN117222663A
(zh)
|
2021-03-03 |
2023-12-12 |
蜻蜓疗法股份有限公司 |
使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
|
|
CA3218829A1
(en)
|
2021-05-19 |
2022-11-24 |
Zhaolong Tong |
Nitrogen-containing compound, conjugate containing said compound, and application thereof
|
|
JP2024525624A
(ja)
|
2021-07-05 |
2024-07-12 |
チャンスー アルファマブ バイオファーマシューティカルズ カンパニー，リミテッド |
抗体薬物コンジュゲート及びその使用
|
|
JP2024525854A
(ja)
|
2021-07-22 |
2024-07-12 |
上海森▲輝▼医▲葯▼有限公司 |
エリブリン誘導体の薬物複合体
|
|
JP2024541058A
(ja)
|
2021-11-03 |
2024-11-06 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． |
抗体の特異的共役
|
|
CN119300856A
(zh)
*
|
2022-02-19 |
2025-01-10 |
萨尔维图斯公司 |
益生菌疫苗和相关使用方法
|
|
AU2023350248A1
(en)
|
2022-09-30 |
2025-04-17 |
Shanghai De Novo Pharmatech Co., Ltd. |
Benzazepine derivative, conjugate containing same, and use thereof
|
|
AU2024210908A1
(en)
|
2023-01-18 |
2025-08-21 |
Tyligand Bioscience (Shanghai) Limited |
Antibody-drug conjugate and use thereof
|
|
WO2024173565A2
(en)
*
|
2023-02-14 |
2024-08-22 |
New York University |
Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
|
|
WO2025019254A1
(en)
|
2023-07-14 |
2025-01-23 |
Guardant Health, Inc. |
Classification of breast tumors using dna methylation from liquid biopsy
|
|
CN120058948A
(zh)
*
|
2023-11-30 |
2025-05-30 |
粤港澳大湾区精准医学研究院(广州) |
一种抗人her2的单克隆抗体及其应用
|